Translational Development Acquisition Corp.

Translational Development Acquisition Corp., whose warrants trade under the ticker TDACW, is a blank-check company focused on the healthcare and life sciences sector, a positioning consistent with the translational medicine framing embedded in its name. The company filed a Form 425 communication on June 29, 2026, under accession number 0001193125-26-286758, a form type required of parties engaged in active business combination communications. The filing adds to the SEC activity record for this vehicle as it advances toward a potential merger target in the life sciences space. For the full sponsor profile, deal timeline, and complete filing history on Translational Development Acquisition Corp., sign up for data access at SpacDesk.